ArticleFrontiers in microbiology2012
Chemosensitization as a means to augment commercial antifungal agents.
Article in Frontiers in microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 88 citations in OpenAlex.
- Cryo-EM structures of Cdr1 reveal snapshots of substrate transport and diverse inhibitor recognition.Science advances · 2026Article
- Soil Reservoirs of Antifungal-Resistant Fungi: Implications for Plant Disease Management with a Focus onMicroorganisms · 2026Review
- Synergistic antifungal effects and mechanisms of amantadine hydrochloride combined with azole antifungal drugs on drug-resistantFrontiers in cellular and infection microbiology · 2025Article
- Yeast Particle Encapsulation of Azole Fungicides for Enhanced Treatment of Azole-ResistantJournal of functional biomaterials · 2024Article
- Potential of phytic acid in synergy with sodium chloride as a natural-borne preservative to inactivateCurrent research in food science · 2024Article
- Article
- Editorial: Use of chemosensitization to augment efficacy of antifungal agents, Volume II.Frontiers in fungal biology · 2023Article
- Fungal Infections as an Uprising Threat to Human Health: Chemosensitization of Fungal Pathogens With AFP FromFrontiers in cellular and infection microbiology · 2022Review
- A Secondary Metabolite Secreted byFrontiers in fungal biology · 2022Article
- Effect of Silver Nanoparticles and L-Carnitine Supplement on Mixed Vaginitis Caused by Candida albicans/ Staphylococcus aureus in Mouse Models: An Experimental Study.Current microbiology · 2021Article
- Antifungal Efficacy of Redox-Active Natamycin against Some Foodborne Fungi-Comparison withFoods (Basel, Switzerland) · 2021Article
- Fungal endophytes in Peperomia obtusifolia and their potential as inhibitors of chickpea fungal pathogens.World journal of microbiology & biotechnology · 2021Article
- Studying the Ability of Thymol to Improve Fungicidal Effects of Tebuconazole and Difenoconazole Against Some Plant Pathogenic Fungi in Seed or Foliar Treatments.Frontiers in microbiology · 2021Article
- Fragments of a Wheat Hevein-Like Antimicrobial Peptide Augment the Inhibitory Effect of a Triazole Fungicide on Spore Germination ofAntibiotics (Basel, Switzerland) · 2020Article
- Flow Cytometric Measurement of Efflux in Candida Species.Current protocols in microbiology · 2020Article
- Assessment of the Sensitivity of Some Plant Pathogenic Fungi to 6-Demethylmevinolin, a Putative Natural Sensitizer Able to Help Overcoming the Fungicide Resistance of Plant Pathogens.Antibiotics (Basel, Switzerland) · 2020Article
- Antifungal Drug Repurposing.Antibiotics (Basel, Switzerland) · 2020Article
- Hevein-Like Antimicrobial Peptides Wamps: Structure-Function Relationship in Antifungal Activity and Sensitization of Plant Pathogenic Fungi to Tebuconazole by WAMP-2-Derived Peptides.International journal of molecular sciences · 2020Article
- Physicochemical and pathohistological changes in experimental fibrosarcoma tumors of hamsters treated with metformin and itraconazole.Oncology letters · 2019Article
- High Efficiency Drug Repurposing Design for New Antifungal Agents.Methods and protocols · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimycotic chemosensitization and its mode of action are of growing interest. Currently, use of antifungal agents in agriculture and medicine has a number of obstacles. Foremost of these is development of resistance or cross-resistance to one or more antifungal agents. The generally high expense and negative impact, or side effects, associated with antifungal agents are two further issues of concern. Collectively, these problems are exacerbated by efforts to control resistant strains, which can evolve into a treadmill of higher dosages for longer periods. This cycle in turn, inflates cost of treatment, dramatically. A further problem is stagnation in development of new and effective antifungal agents, especially for treatment of human mycoses. Efforts to overcome some of these issues have involved using combinations of available antimycotics (e.g., combination therapy for invasive mycoses). However, this approach has had inconsistent success and is often associated with a marked increase in negative side effects. Chemosensitization by natural compounds to increase effectiveness of commercial antimycotics is a somewhat new approach to dealing with the aforementioned problems. The potential for safe natural products to improve antifungal activity has been observed for over three decades. Chemosensitizing agents possess antifungal activity, but at insufficient levels to serve as antimycotics, alone. Their main function is to disrupt fungal stress response, destabilize the structural integrity of cellular and vacuolar membranes or stimulate production of reactive oxygen species, augmenting oxidative stress and apoptosis. Use of safe chemosensitizing agents has potential benefit to both agriculture and medicine. When co-applied with a commercial antifungal agent, an additive or synergistic interaction may occur, augmenting antifungal efficacy. This augmentation, in turn, lowers effective dosages, costs, negative side effects and, in some cases, countermands resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.